Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists …
Breast cancer is increasingly prevalent in older adults and is a substantial part of routine
oncology practice. However, management of breast cancer in this population is challenging …
oncology practice. However, management of breast cancer in this population is challenging …
Anticancer drugs are not well tolerated in all older patients with cancer
Studies on new anticancer drugs often inappropriately conclude that these treatments are
well tolerated and feasible in the older population with cancer, despite the drug being …
well tolerated and feasible in the older population with cancer, despite the drug being …
Outcomes of older women with hormone receptor–positive, human epidermal growth factor receptor–negative metastatic breast cancer treated with a CDK4/6 inhibitor …
LJ Howie, H Singh, E Bloomquist, S Wedam… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6)
inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval …
inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval …
[HTML][HTML] Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
V Di Lauro, G Barchiesi, F Martorana, G Zucchini… - ESMO open, 2022 - Elsevier
Background Evaluation of health-related quality of life (HR-QoL) among cancer patients has
gained an increasing importance and is now a key determinant of anticancer treatments' …
gained an increasing importance and is now a key determinant of anticancer treatments' …
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative …
Purpose Abemaciclib in combination with endocrine therapy (ET) has demonstrated
significant efficacy benefits in HR+, HER2− advanced breast cancer patients in the Phase 3 …
significant efficacy benefits in HR+, HER2− advanced breast cancer patients in the Phase 3 …
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient …
C Palmieri, A Musson, C Harper-Wynne… - British Journal of …, 2023 - nature.com
Abstract Background The Ibrance® Patient Program was established to provide access to
palbociclib for UK National Health Service (NHS) patients with metastatic breast cancer …
palbociclib for UK National Health Service (NHS) patients with metastatic breast cancer …
[HTML][HTML] Palbociclib in combination with aromatase inhibitors in patients≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 …
S El Badri, B Tahir, K Balachandran, P Bezecny… - The Breast, 2021 - Elsevier
Background Breast cancer incidence increases with age and real-world data is essential to
guide prescribing practices in the older population. The aim of this study was to collect large …
guide prescribing practices in the older population. The aim of this study was to collect large …
Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis
L Lei, Y Huang, L Shi, W Ye, X Lv, L Ying, X Yu… - Breast Cancer Research …, 2024 - Springer
Purpose Endocrine therapy is the anti-tumor therapy for human breast cancer but endocrine
resistance was a major burden. It has been reported that Palbociclib and fulvestrant can be …
resistance was a major burden. It has been reported that Palbociclib and fulvestrant can be …
An overview of the roles of CDK4/6 inhibitors in metastatic breast cancer elderly patients
C Pacilio, G Rosati, A Crispo, S Bimonte, F DI RELLA… - in vivo, 2023 - iv.iiarjournals.org
Breast cancer is the most common type of cancer in women worldwide. Many studies
indicate that breast cancer increases in elderly patients (≥ 70 years) and suggest that the …
indicate that breast cancer increases in elderly patients (≥ 70 years) and suggest that the …
[HTML][HTML] The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
F Petrelli, L Dottorini, G Di Menna, K Borgonovo… - The Breast, 2023 - Elsevier
Abstract Introduction Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have an extremely
important impact on the treatment of hormone-sensitive breast cancer (BC) and have …
important impact on the treatment of hormone-sensitive breast cancer (BC) and have …